Back

GLP1 receptor agonists and CAD regression in diabetic patients after ACS

31 August 2025 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Diabetes and coronary artery disease Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Mauro Gitto

Humanitas University, Milan (Italy)

6 More presentations in this session

Presentation thumbnail
Differential effects of glucose-lowering agents on atherosclerotic plaque progression in diabetic patients: a retrospective cohort study using serial coronary CT angiography
Doctor J. Zhang (Chengdu, CN)
Abstract Slides Video
Presentation thumbnail
Participant-level pericoronary adipose tissue attenuation predicts changes in plaque composition: a 1-year prospective study in asymptomatic individuals with type 2 diabetes mellitus
Doctor K. Overgaard (Svendborg, DK)
Abstract Slides Video
Presentation thumbnail
Glycemic control and renal function decline in patients with chronic coronary syndrome
Doctor C. HUANG (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Impact of prediabetes on long-term outcomes after percutaneous coronary interventions
Doctor E. Steinacher (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Diabetes status and grade of left ventricular ejection fraction as predictors of outcomes in patients with Non-ST-segment elevation myocardial infarction
Professor Y. Kim (Chuncheon, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes and coronary artery disease

The Event

Event poster

ESC Congress 2025

31 August 2025 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Association of sodium-glucose cotransporter-2 inhibitor with regression of coronary plaque burden
thumbnail
Congress Presentation
GLP-1 RAs reduce mortality and cardiovascular events across the spectrum of treated patients: a systematic review and meta-analysis
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources